Compare Novo Nordisk A/S (NVO) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Defense Tech ETF — how do they compare? Novo Nordisk A/S trades at $44.87 (market cap $200.69B), while Global X Defense Tech ETF trades at $61.96. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Global X Defense Tech ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SHLD | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $78.02 |
52-Week Low | $35.29 | $58.20 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SHLD (Global X Defense Tech ETF) trades at $62.72, down 0.41% on the day, with a bearish technical signal overall despite oversold RSI readings. The ETF offers diversified exposure to global defense technology firms, with institutional buying interest noted in recent filings. Key support sits at $62, while resistance is at $63-$64.
Outlook is supported by rising global defense spending and geopolitical shifts, but risks include high launch costs for space-related holdings and ETF expense comparisons. The technical setup suggests potential for a near-term rebound from oversold levels, though moving averages remain bearish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
